Tech Company M&A Transactions
Kos Pharmaceuticals Acquisition
Kos Pharmaceuticals, operating out of Cranbury, was acquired by Abbott Laboratories. The acquisition price was $3.7 million.
Transaction Overview
Company Name
Acquired By
Announced On
11/8/2006
Transaction Type
M&A
Amount
$3,700,000
M&A Terms
Abbott's (NYSE: ABT) offer of $78 a share is above Kos' Tuesday close of $77. The 52-week high was $77.30 in that day's interday trading. The 52-week low was $36.07 on June 14. This acquisition expands Abbott's presence in the lipid-management market and will provide several on-market and late-stage pipeline products.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1 Cedar Brook Drive
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
Kos Pharmaceuticals, Inc. - named after the Greek island where Hippocrates founded the science of medicine -- is a fully integrated specialty pharmaceutical company engaged in the development of proprietary prescription pharmaceutical products, principally for treatment of cardiovascular, respiratory and metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Miles White
Browse more venture capital transactions:
Prev: 11/8/2006: AlterPoint venture capital transaction
Next: 11/8/2006: Solstice Neurosciences venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs